Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity

Biochimica et Biophysica Acta - Biomembranes

Volumn 1828, Issue 5, 2013, Pages 1396-1404

  Dalla Pozza, Elisa ^a   Lerda, Carlotta ^b   Costanzo, Chiara ^a   Donadelli, Massimo ^a   Dando, Ilaria ^a   Zoratti, Elisa ^a   Scupoli, Maria Teresa ^a   Beghelli, Stefania ^a   Scarpa, Aldo ^a   Fattal, Elias ^c   Arpicco, Silvia ^b   Palmieri, Marta ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIV PARIS SUD   (France)

Author keywords

CD44; Endocytosis; Gemcitabine; Hyaluronic acid conjugated liposomes; Lipid raft; Pancreatic cancer

Indexed keywords

GEMCITABINE; HERMES ANTIGEN; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL TRANSPORT; CONFOCAL MICROSCOPE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; LIPOSOMAL DELIVERY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADENOCARCINOMA; ANIMALS; ANTIGENS, CD44; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CHOLESTEROL; DEOXYCYTIDINE; FLOW CYTOMETRY; HUMANS; HYALURONIC ACID; LIPOSOMES; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; PANCREATIC NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; PRODRUGS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875141357     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2013.01.020     Document Type: Article

References (51)

1. J.P. Neoptolemos, D.D. Stocken, H. Friess, C. Bassi, J.A. Dunn, H. Hickey, H. Beger, L. Fernandez-Cruz, C. Dervenis, F. Lacaine, M. Falconi, P. Pederzoli, A. Pap, D. Spooner, D.J. Kerr, and M.W. Buchler A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N. Engl. J. Med. 350 2004 1200 1210
2. M.W. Saif Pancreatic neoplasm in 2011: an update JOP 12 2011 316 321
3. A.D. Rhim, E.T. Mirek, N.M. Aiello, A. Maitra, J.M. Bailey, F. McAllister, M. Reichert, G.L. Beatty, A.K. Rustgi, R.H. Vonderheide, S.D. Leach, and B.Z. Stanger EMT and dissemination precede pancreatic tumor formation Cell 148 2012 349 361
4. C.J. Lee, J. Dosch, and D.M. Simeone Pancreatic cancer stem cells J. Clin. Oncol. 26 2008 2806 2812
5. C. Li, D.G. Heidt, P. Dalerba, C.F. Burant, L. Zhang, V. Adsay, M. Wicha, M.F. Clarke, and D.M. Simeone Identification of pancreatic cancer stem cells Cancer Res. 67 2007 1030 1037
6. H.A. Burris III, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, P. Tarassoff, R. Nelson, F.A. Dorr, C.D. Stephens, and D.D. Von Hoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15 1997 2403 2413
7. M. Zoller CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 11 2011 254 267
8. E. Auzenne, S.C. Ghosh, M. Khodadadian, B. Rivera, D. Farquhar, R.E. Price, M. Ravoori, V. Kundra, R.S. Freedman, and J. Klostergaard Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts Neoplasia 9 2007 479 486
9. Y. Luo, and G.D. Prestwich Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate Bioconjug. Chem. 10 1999 755 763
10. Y. Luo, M.R. Ziebell, and G.D. Prestwich A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells Biomacromolecules 1 2000 208 218
11. A. Kumar, B. Sahoo, A. Montpetit, S. Behera, R.F. Lockey, and S.S. Mohapatra Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides Nanomedicine 3 2007 132 137
12. H. Lee, H. Mok, S. Lee, Y.K. Oh, and T.G. Park Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels J. Control. Release 119 2007 245 252
13. A.K. Yadav, A. Agarwal, G. Rai, P. Mishra, S. Jain, A.K. Mishra, H. Agrawal, and G.P. Agrawal Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil Drug Deliv. 17 2010 561 572
14. A.K. Yadav, P. Mishra, A.K. Mishra, P. Mishra, S. Jain, and G.P. Agrawal Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin Nanomedicine 3 2007 246 257
15. R.E. Eliaz, and F.C. Szoka Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells Cancer Res. 61 2001 2592 2601
16. Y. Glucksam-Galnoy, T. Zor, and R. Margalit Hyaluronan-modified and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-inflammatory response J. Control. Release 160 2012 388 393
17. D. Peer, and R. Margalit Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models Int. J. Cancer 108 2004 780 789
18. D. Peer, and R. Margalit Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia 6 2004 343 353
19. E. Cukierman, and D.R. Khan The benefits and challenges associated with the use of drug delivery systems in cancer therapy Biochem. Pharmacol. 80 2010 762 770
20. X. Xu, A.K. Jha, D.A. Harrington, M.C. Farach-Carson, and X. Jia Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks Soft Matter 8 2012 3280 3294
21. M.L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs J. Control. Release 100 2004 331 346
22. N. Marina-Garcia, L. Franchi, Y.G. Kim, Y. Hu, D.E. Smith, G.J. Boons, and G. Nunez Clathrin- and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation J. Immunol. 182 2009 4321 4327
23. H.S. Qhattal, and X. Liu Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes Mol. Pharm. 8 2011 1233 1246
24. B. Schneider, C. Schueller, O. Utermoehlen, and A. Haas Lipid microdomain-dependent macropinocytosis determines compartmentation of Afipia felis Traffic 8 2007 226 240
25. R.D. Singh, V. Puri, J.T. Valiyaveettil, D.L. Marks, R. Bittman, and R.E. Pagano Selective caveolin-1-dependent endocytosis of glycosphingolipids Mol. Biol. Cell 14 2003 3254 3265
26. M. Donadelli, C. Costanzo, S. Beghelli, M.T. Scupoli, M. Dandrea, A. Bonora, P. Piacentini, A. Budillon, M. Caraglia, A. Scarpa, and M. Palmieri Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine Biochim. Biophys. Acta 1773 2007 1095 1106
27. S.T. Jalkanen, R.F. Bargatze, L.R. Herron, and E.C. Butcher A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man Eur. J. Immunol. 16 1986 1195 1202
28. Y. Shimizu, G.A. Van Seventer, R. Siraganian, L. Wahl, and S. Shaw Dual role of the CD44 molecule in T cell adhesion and activation J. Immunol. 143 1989 2457 2463
29. J.E. Draffin, S. McFarlane, A. Hill, P.G. Johnston, and D.J. Waugh CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells Cancer Res. 64 2004 5702 5711
30. S. Goodison, V. Urquidi, and D. Tarin CD44 cell adhesion molecules Mol. Pathol. 52 1999 189 196
31. U. Gunthert, M. Hofmann, W. Rudy, S. Reber, M. Zoller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells Cell 65 1991 13 24
32. S. Misra, P. Heldin, V.C. Hascall, N.K. Karamanos, S.S. Skandalis, R.R. Markwald, and S. Ghatak Hyaluronan-CD44 interactions as potential targets for cancer therapy FEBS J. 278 2011 1429 1443
33. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
34. F.M. Muggia Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention Clin. Cancer Res. 5 1999 7 8
35. R. Sinha, G.J. Kim, S. Nie, and D.M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery Mol. Cancer Ther. 5 2006 1909 1917
36. T. Pouyani, and G.D. Prestwich Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials Bioconjug. Chem. 5 1994 339 347
37. K.P. Vercruysse, and G.D. Prestwich Hyaluronate derivatives in drug delivery Crit. Rev. Ther. Drug Carrier Syst. 15 1998 513 555
38. E.N. Harris, S.V. Kyosseva, J.A. Weigel, and P.H. Weigel Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE) J. Biol. Chem. 282 2007 2785 2797
39. V.M. Platt, and F.C. Szoka Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor Mol. Pharm. 5 2008 474 486
40. S. Banerji, A.J. Wright, M. Noble, D.J. Mahoney, I.D. Campbell, A.J. Day, and D.G. Jackson Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction Nat. Struct. Mol. Biol. 14 2007 234 239
41. J. Lesley, V.C. Hascall, M. Tammi, and R. Hyman Hyaluronan binding by cell surface CD44 J. Biol. Chem. 275 2000 26967 26975
42. S. Mizrahy, S.R. Raz, M. Hasgaard, H. Liu, N. Soffer-Tsur, K. Cohen, R. Dvash, D. Landsman-Milo, M.G. Bremer, S.M. Moghimi, and D. Peer Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response J. Control. Release 156 2011 231 238
43. K.L. Douglas, C.A. Piccirillo, and M. Tabrizian Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors Eur. J. Pharm. Biopharm. 68 2008 676 687
44. J. Rejman, A. Bragonzi, and M. Conese Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes Mol. Ther. 12 2005 468 474
45. C.A. Eyster, J.D. Higginson, R. Huebner, N. Porat-Shliom, R. Weigert, W.W. Wu, R.F. Shen, and J.G. Donaldson Discovery of new cargo proteins that enter cells through clathrin-independent endocytosis Traffic 10 2009 590 599
46. S. Oliferenko, K. Paiha, T. Harder, V. Gerke, C. Schwarzler, H. Schwarz, H. Beug, U. Gunthert, and L.A. Huber Analysis of CD44-containing lipid rafts: recruitment of annexin II and stabilization by the actin cytoskeleton J. Cell Biol. 146 1999 843 854
47. T. Murai, Y. Maruyama, K. Mio, H. Nishiyama, M. Suga, and C. Sato Low cholesterol triggers membrane microdomain-dependent CD44 shedding and suppresses tumor cell migration J. Biol. Chem. 286 2011 1999 2007
48. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, and M.N. Raber A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J. Clin. Oncol. 9 1991 491 498
49. J.M. Reid, W. Qu, S.L. Safgren, M.M. Ames, M.D. Krailo, N.L. Seibel, J. Kuttesch, and J. Holcenberg Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors J. Clin. Oncol. 22 2004 2445 2451
50. R. Moog, A.M. Burger, M. Brandl, J. Schuler, R. Schubert, C. Unger, H.H. Fiebig, and U. Massing Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels Cancer Chemother. Pharmacol. 49 2002 356 366
51. C. Surace, S. Arpicco, A. Dufay-Wojcicki, V. Marsaud, C. Bouclier, D. Clay, L. Cattel, J.M. Renoir, and E. Fattal Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells Mol. Pharm. 6 2009 1062 1073